Skip to main content
Parker Cancer ends here
Point of View

A New Wave of Clinical Trials in Immuno-Oncology: Collaborative Group Trials

March 5, 2019
A New Wave of Clinical Trials in Immuno-Oncology: Collaborative Group Trials

Panelists:

  • Theresa LaVallee, PhD, Vice President, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy
  • Kim Blackwell, MD, Vice President of Early Phase Development and Immuno-oncology, Lilly Oncology
  • George Sledge, MD, Professor, Division Chief, Stanford University Medical Center

Clinical research is facing a new landscape of challenges. Over a thousand ongoing immuno-oncology clinical trials are enrolling a limited pool of cancer patients. New data emerges regularly that could inform drug discovery. How can clinical trials evolve to translate discoveries to treatments in a sustainable way? Experts representing the industry, academic and nonprofit perspectives discuss how collaboration can unite the strengths of each research pillar to effectively design a clinical trial with science and patients at the core. This talk was recorded at the Precision Medicine World Conference in January 2019 in Silicon Valley.